Clinical Trials Logo

Plaque, Atherosclerotic clinical trials

View clinical trials related to Plaque, Atherosclerotic.

Filter by:

NCT ID: NCT06313645 Recruiting - Clinical trials for Coronary Artery Disease

Vascular Senescence and Atherosclerotic Plaque Vulnerability

VICTORIA
Start date: July 1, 2023
Phase:
Study type: Observational

Chronological aging significantly contributes to structural and functional alterations in the vasculature, making it a major risk factor for atherosclerotic disease and its acute thrombotic events. DNA damage, including telomeric, non-telomeric, and mitochondrial damage, is recognized as a key initiator of vascular aging and atherogenesis. There is abundant evidence indicating the presence of oxidative DNA lesions, telomere erosion, and mitochondrial DNA damage in both experimental and human plaques, as well as in the peripheral cells of atherosclerotic patients. It is increasingly evident that genomic instability activates signaling pathways that lead to a multitude of pathophysiological cellular and molecular changes. These changes promote inflammation, apoptosis, autophagy, and ultimately, cellular senescence, accompanied by the "senescence-associated secretory phenotype" (SASP). However, the precise mechanisms linking the DNA damage response (DDR) to senescence, SASP in vascular cells, and the pathogenesis of atherosclerosis and vulnerable atheroma are yet to be fully understood. Additional research is needed to delineate the underlying mechanisms through which mitochondrial dysfunction influences telomere length and vice versa, and how their interaction contributes to the vascular aging process. Progress in this area has the potential to uncover therapeutic targets and novel, more precise diagnostic, and prognostic indicators. The objectives of the VICTORIA study are to examine the levels of aging-related non-coding RNA deregulation (specifically lncRNA TERRA and mitomiR) and peripheral markers of cell aging (including telomere length and mitochondrial DNA content) across the various spectra of angina pectoris (stable angina, unstable angina, NSTEMI, and STEMI). Additionally, the study aims to determine whether these markers are correlated with vulnerable plaque characteristics and major adverse cardiovascular events.

NCT ID: NCT06305559 Not yet recruiting - Clinical trials for Coronary Artery Disease

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

REMBRANDT
Start date: March 2024
Phase: Phase 3
Study type: Interventional

This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).

NCT ID: NCT06280976 Recruiting - Clinical trials for Coronary Artery Disease

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

ARTCAP
Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effect medication on your heart. All patients between 18-80 years of age, at intermediate or high risk for coronary heart disease (calculated based on age, gender, race, and history of smoking, diabetes, high blood pressure, high cholesterol, family history of early coronary heart disease) with/without symptoms suggestive of heart disease, including chest pain or shortness of breath on exertion, will be selected to take part in this study. CT scan will be used to assess to see if the prescribed treatment changes the blood vessels in heart. The investigators are doing this study because they want to develop better tools to predict, diagnose, and treat coronary heart disease. This research will help improve care for patients with coronary heart disease by evaluating heart vessel narrowing and improving the decision-making for treatment.

NCT ID: NCT06275399 Recruiting - Atherosclerosis Clinical Trials

Comprehensive Assessment of Morphometric, Functional, Biomechanical and Biological Interactions Between Atherosclerotic Plaque and Platelets Within the Stenosed Coronary Artery

INTERFORCE
Start date: July 21, 2023
Phase:
Study type: Observational [Patient Registry]

The main objective of the present study is to verify, in vivo, whether shear forces computed solely based on coronary angiography and computational fluid dynamics (CFD) techniques are associated with the biomarkers indicating the prothrombotic tendency of circulating blood in situ - distally and proximally to the coronary stenosis. The study will prospectively assess the relationship between i) the value and distribution of shear rate and shear stress (SS) estimated using three-dimensional angiography and CFD techniques, and ii) atherosclerotic plaque characteristics as assessed by optical coherence tomography (OCT), iii) functional parameters of diseased vessels assessed by vessel fractional flow reserve (vFFR), and iv) in situ platelet activation, as expressed by platelet-derived microvesicles (pMVs) and small extracellular vesicles (sEVs), platelet aggregometry and other serum prothrombotic or inflammatory biomarkers sampled within the coronary artery.

NCT ID: NCT06214754 Completed - Clinical trials for Patients With Atherosclerotic Plaques in the Coronary Arteries That Require Excision

Efficacy and Safety of Intravascular High-pressure Cutting Balloon Catheters for PCI

Start date: June 16, 2023
Phase: N/A
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of intravascular high-pressure cut balloon catheter compared to cut balloon catheter during PCI, and to support product registration and clinical application.

NCT ID: NCT06194526 Enrolling by invitation - Coronary Stenosis Clinical Trials

Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography

CORPLAQ-TRAIT
Start date: September 19, 2023
Phase:
Study type: Observational

The present clinical study aims to identify transcriptomic patterns derived from whole blood samples related to coronary atherotic burden. Additionally, as a secondary analysis, the research team will explore the algorithm's ability to detect the presence of aortic disease and pro-inflammatory cardiometabolic alterations, such as hepatic steatosis and surrogate markers of coronary inflammation.

NCT ID: NCT06080256 Not yet recruiting - Stenosis Clinical Trials

Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)

EAST-aICAS
Start date: December 30, 2023
Phase: Phase 3
Study type: Interventional

The primary goal of the trial is to investigate whether the lipid lowering strategy using Alirocumab plus statin could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 6 months of follow-up, in patients with asymptomatic intracranial artery stenosis.

NCT ID: NCT06037889 Recruiting - Clinical trials for Branch Atheromatous Disease

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

BRANT
Start date: November 9, 2023
Phase: Phase 3
Study type: Interventional

Branch atheromatous disease (BAD)-related stroke, characterized by subcortical single infarcts without severe stenosis of the large artery, but with a clear atherosclerotic mechanism, is now regarded as a separate stroke type. BAD is associated with early neurological deterioration and poor prognosis, but is lack of effective therapy. The goal of this randomized controlled trial is to test the efficacy and safety of intravenous tirofiban in patients with acute ischemic stroke caused by branch atheromatous disease. The main question it aims to answer is: Compared with standard antiplatelet therapy based on current stroke guideline, whether tirofiban used in acute phase of BAD could improve the proportion of excellent functional outcome (modified Rankin Scale: 0-1) at 90 days. Researcher will also compare the rate of major bleeding between treatment and control groups.

NCT ID: NCT06025305 Enrolling by invitation - Clinical trials for Coronary Artery Disease

Identifying Vulnerable CoronAry PLaqUes With Artificial IntElligence-assisted CT Angiography

VALUE
Start date: July 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to develop an automatic whole-process AI model to detect, quantify, and characterize plaques using coronary CT angiography in coronary artery disease patients. The main questions it aims to answer are: 1. Whether the AI model enables to detect and quantify coronary plaques compared with intravascular ultrasound or expert readers; 2. Whether the AI model enables to identify vulnerable plaques using intravascular ultrasound or optical coherence tomography as the reference standard. 3. Whether the AI model enables to predict future adverse cardiac events in a large cohort of 10,000 patients with non-obstructive CAD.

NCT ID: NCT05975554 Recruiting - Clinical trials for Carotid Atherosclerosis

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

ELLIPSE
Start date: August 26, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trail is to compare the differences in carotid plaque Treg cells' gene signature for activation, proliferation, and suppressive function using scRNA-seq in patients treated with IL-2 compared to control.